RIBOMIC Inc. is engaged in the drug discovery business based on the platform Ribomic Aptamer Refined Therapeutics System related to aptamer drug discovery technology. Its drug discovery business is divided into self discovery and co-discovery divisions. Self Drug Discovery division develops aptamer and licenses and out the results to pharmaceutical companies. The Co-Discovery division earns the research expenses paid by the alliance partner for the shared part of co-discovery business with alliance pharmaceutical companies researching aptamer pharmaceutical.

Employees

Sector

Biotechnology & Medical Research

Calendar

12/11 Earnings release - Q2 2027

More about the company

Quotes

Date	Price	Change	Volume
02/26/02	JP¥76.00	-5.00%	6,21,900
01/26/01	JP¥80.00	0.00%	2,74,800
30/26/30	JP¥80.00	+2.56%	5,95,100
29/26/29	JP¥78.00	+1.30%	5,06,500
28/26/28	JP¥77.00	+1.32%	2,09,100

Delayed Quote Japan Exchange

More quotes

Annual profits - Rate of surprise

Company calendar

Market Closed - Japan Exchange 12:00:00 02/10/2026 pm IST			5-day change	1st Jan Change
76.00 ^JPY	-5.00%		0.00%	-2.56%

25/08	Ribomic Announces Completion of Clinical Trial Site Establishment for the Phase 3 Clinical Trial of Umedaptanib Pegol in Achondroplasia	CI
13/08	Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2027	CI

Market Cap	429.77Cr 2.72Cr 2.42Cr 2.26Cr 2.06Cr 3.88Cr 261.95Cr 3.92Cr 27Cr 11Cr 133.91Cr 10Cr 10Cr	P/E 2025	-3.89x	P/E 2026	-3.82x
Enterprise Value	147.07Cr 93.25L 82.85L 77.33L 70.48L 1.33Cr 90Cr 1.34Cr 9.36Cr 3.63Cr 46Cr 3.5Cr 3.42Cr	EV / Sales 2025	666x	EV / Sales 2026	651x
Free-Float	96.61%	Yield 2025 *	-	Yield 2026	-

25/08	Ribomic Announces Completion of Clinical Trial Site Establishment for the Phase 3 Clinical Trial of Umedaptanib Pegol in Achondroplasia	CI
13/08	Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2027	CI
13/08	Ribomic Inc. Reports Earnings Results for the First Quarter Ended June 30, 2026	CI
02/07	Ribomic Enrolls First Patient in Phase III Trials of Umedaptanib Pegol for Achondroplasia Treatment	MT
02/07	Ribomic Inc. Announces First Patient Enrollment In Phase 3 Clinical Trial Of Umedaptanib Pegol For Achondroplasia	CI
14/05	Ribomic Inc. Reports Earnings Results for the Full Year Ended March 31, 2026	CI
19/03	Ribomic Files IND For Phase III Trial Of Achondroplasia Drug In Japan	MT
19/03	Ribomic Inc Announces IND Application for Phase III Clinical Trial of Umedaptanib Pegol for Achondroplasia Treatment	CI
10/03	Ribomic Reports Positive Phase II Results For Achondroplasia Drug	MT
10/03	Ribomic, Inc. Announces Summary Report on Primary Endpoint for Phase Ii Clinical Trial of Umedaptanib Pegol in the Treatment of Achondroplasia	CI
12/02	Ribomic Inc. Reports Earnings Results for the Nine Months Ended December 31, 2025	CI
14/01	Ribomic Files Patent for Anti-Autotaxin Aptamer RBM-006	MT
14/01	RIBOMIC, Inc. Announces New Substance Patent Application for Highly Active RBM-006 (Anti-Autotaxin Aptamer) and its Drug Impact in a Mouse Model of Diabetic Retinopathy	CI

07/25/07	RIBOMIC Announces Positive Phase 2 Cohort 2 Results for Umedaptanib Pegol in Achondroplasia, Demonstrating an Increase in the Annualized Growth Rate of up to +5.0 cm/year with Biweekly Administration in Children Aged 5 Years and Older	BU
05/24/05	RIBOMIC Announces Positive Interim Results from Phase IIa Trial of umedaptanib pegol in Achondroplasia Demonstrating Increase in Annualized Growth Rate of up to +4.6 cm/year in Children 5 Years of Age and Older in the Low Dose Cohort	BU
03/24/03	RIBOMIC Announces Completion of Patient Enrollment in Early Phase II Study of umedaptanib pegol for Achondroplasia and Initiation of Dosing in Cohort 2 of Early Phase II Clinical Study	BU
05/23/05	RIBOMIC Phase I and II Data Published in the Eye: Full TOFU/RAMEN/TEMPURA Trial Results Demonstrate Clinical Proof of Concept of Umedaptanib Pegol in Exudative Age-Related Macular Degeneration (nAMD)	BU
29/22/29	RIBOMIC : Announces Issuance of US Patent for its RBM-010, Novel Drug Candidate for Osteoarthritis	PU

Ribomic Inc. Share Price

Stocks

4591

JP3974850004

Biotechnology & Medical Research

Valuation: Ribomic Inc.

Chart: Ribomic Inc.

Latest news: Ribomic Inc.

Press Releases: Ribomic Inc.

News in other languages: Ribomic Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Ribomic Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

08/25/08	RIBOMIC veröffentlicht positive Ergebnisse der Phase-2-Kohorte 2 für Umedaptanib Pegol bei Achondroplasie, die eine Steigerung der annualisierten Wachstumsrate um bis zu +5,0 cm/Jahr bei zweiwöchentlicher Verabreichung bei Kindern ab 5 Jahren zeigen
06/24/06	RIBOMIC gibt positive Zwischenergebnisse der Phase-IIa-Studie mit Umedaptanib Pegol bei Achondroplasie bekannt, die eine Steigerung der annualisierten Wachstumsrate von bis zu +4,6 cm/Jahr bei Kindern ab 5 Jahren in der niedrig dosierten...
20/20/20	RIBOMIC : kündigt erste Injektion in der klinischen Phase-2-Studie von RBM-007 (TOFU-Studie) bei Patienten mit feuchter altersbedingter Makula-Degeneration an
19/19/19	RIBOMIC : gibt positive Topline-Ergebnisse der klinischen Phase-1/2a-Studie an RBM-007 (SUSHI-Studie) bei Patienten mit feuchter altersbedingter Makuladegeneration bekannt

1 day	-5.00%
Current month	-5.00%
1 month	-8.43%
3 months	+15.15%
6 months	-15.56%
Current year	-2.56%

1 week	74	80
1 month	74	88
Current year	57	120
1 year	57	120
3 years	57	141
5 years	57	944
10 years	57	1,109

Manager	Title	Age	Since
Yoshikazu Nakamura PSD	President	78	01/04/2012
Toshiya Imai DFI	Director of Finance/CFO	-	-
Takeo Adachi CTO	Chief Tech/Sci/R&D Officer	39	01/10/2023

Director	Title	Age	Since
Yoshikazu Nakamura BRD	Director/Board Member	78	01/10/2005
Toshiaki Nishihata BRD	Director/Board Member	77	01/06/2016
Takeo Adachi BRD	Director/Board Member	39	01/06/2024

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
RIBOMIC INC.	-5.00%	0.00%	-20.83%	-40.16%	2.72Cr
WUXI APPTEC CO., LTD.	+4.16%	+3.04%	+49.37%	+94.17%	7.42TCr
ARGENX SE	-3.11%	-3.53%	+20.19%	+81.44%	5.74TCr
LONZA GROUP AG	+0.89%	-0.63%	+2.17%	+36.19%	4.76TCr
REVOLUTION MEDICINES, INC.	+0.36%	+0.81%	+342.39%	+742.40%	4.43TCr
IQVIA HOLDINGS INC.	-0.96%	-4.50%	+24.96%	+35.38%	4.25TCr
BEONE MEDICINES AG	-0.20%	-0.77%	+4.13%	+105.50%	4.07TCr
CELLTRION, INC.	-0.54%	+2.93%	+9.31%	+50.41%	3.1TCr
WUXI BIOLOGICS (CAYMAN) INC.	-2.68%	+2.92%	+29.33%	+22.72%	2.85TCr
BIONTECH SE	+0.05%	-1.64%	-8.14%	-11.37%	2.43TCr
Average	-0.70%	-0.53%	+45.29%	+111.67%	3.91TCr
Weighted average by Cap.	+0.12%	-0.84%	+56.95%	+138.25%

	2025	2026
Net sales	20L 12.68T 11.27T 10.52T 9.58T 18.08T 12.19L 18.24T 1L 49.31T 6L 47.61T 46.58T	30L 19.02T 16.9T 15.77T 14.38T 27.11T 18.29L 27.37T 2L 73.97T 9L 71.41T 69.86T
Net income	-101.8Cr -64.54L -57.35L -53.52L -48.79L -92.01L -62Cr -92.87L -6.48Cr -2.51Cr -32Cr -2.42Cr -2.37Cr	-114.5Cr -72.6L -64.5L -60.2L -54.87L -1.03Cr -70Cr -1.04Cr -7.29Cr -2.82Cr -36Cr -2.73Cr -2.67Cr
Net Debt	-303.7Cr -1.93Cr -1.71Cr -1.6Cr -1.46Cr -2.74Cr -185.11Cr -2.77Cr -19Cr -7.49Cr -95Cr -7.23Cr -7.07Cr	-282.7Cr -1.79Cr -1.59Cr -1.49Cr -1.35Cr -2.56Cr -172.31Cr -2.58Cr -18Cr -6.97Cr -88Cr -6.73Cr -6.58Cr